New trial for MDR-TB regimen

May 16, 2017

The Pragmatic Clinical Trial for More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (TB-PRACTECAL) is a multi-center, open label, multi-arm, randomized, controlled phase II-III trial. TB-PRACTECAL, a Médecins Sans Frontières (MSF) sponsored clinical trial, aims to evaluate short treatment regimens that contain bedaquiline and pretomanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary MDR-  and XDR-TB. 

 

The treatment is for six months and the trial’s first patient was randomized and started treatment on January 17, 2017. Additional information on the trial can be found here

 

 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

4-month regimen of rifampin was not inferior to the 9-month regimen of isoniazid for the prevention of active tuberculosis and was associated with a h...

August 3, 2018

1/3
Please reload

Recent Posts
Please reload

Archive
Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
Social media

Get in touch via twitter  @actnet_tb 

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Pinterest Social Icon
  • Instagram Social Icon